Erectile Dysfunction (ED) Drugs Market to Grow with

0

Erectile Dysfunction (ED) Drugs Market: Introduction

According to the report, the global erectile dysfunction drugs market was valued at US$3.4 billion in 2017 and is projected to contract at a CAGR of -3.1% from 2021 to 2028. type 5 are one of the most commonly used erectile drugs. Dysfunction medications across the world. Sildenafil citrate and other PDE 5 inhibitors such as tadalafil and Levitra/Staxyn (vardenafil) are the most widely consumed drugs for the treatment of erectile dysfunction in the world. By losing patent and marketing exclusivity, these drugs will become available in the public domain as low-cost generics.

Get the report brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1550

The loss of patent exclusivity for a brand name drug leads to a reduction in revenue of approximately 40% in the first year, which continues to decrease to 30% and 20% in subsequent years. This can be attributed to the fact that the generic equivalents of these drugs are manufactured and marketed at 1/10th the price of the original branded drug, resulting in much higher consumption of the drugs since efficacy and demand remain high. . Therefore, the generics segment should be a promising investment area even for original molecule manufacturers, since it is a mode of subsistence and expense compensation.

Pfizer also plans to market it in other countries in the developing world. Bayer AG introduced the orally disintegrating tablet for its drug Levitra (vardenafil) in Germany, France, Austria, Hungary, Spain, Sweden, Poland, Denmark and Great Britain in March 2011.

Additionally, Asia-Pacific and the rest of the world are favorable regions for generic companies to initiate, establish and expand business due to lower barriers to entry and shorter legal hurdles. Large populations, availability of raw materials, and cheaper labor have enhanced the manufacturing capabilities of these companies.

The global erectile dysfunction drugs market is expected to experience a patent cliff towards the end of the forecast period. The market is strongly generic until 2019 due to the expiration of patents in these countries. However, it is still blockbuster drugs such as Sildenafil Citrate, Tadalafil and Levitra/Staxyn (vardenafil) in the United States that have driven the market in recent years. tadalafil and Levitra/Staxyn (vardenafil) are expected to lose marketing and patent exclusivity in 2017 and 2018, respectively, while sildenafil citrate is expected to expire in the United States by October 2020. This event is expected to have a profound effect on the overall market for Erectile Dysfunction Drugs leading to drastic decline in market revenue by the end of forecast period. In addition, ANDAs approved for these molecules will lead to intense generic competition.

Get a personalized research report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=1550

Increased incidence of various diseases and sedentary lifestyles

The number of patients suffering from diabetes mellitus, hypertension, high cholesterol, spinal cord injury, cardiovascular disease and various other conditions is increasing globally. Rising incidence rates of diseases and their associated drug treatments are affecting normal functioning in men, thus contributing to the rise in demand for erectile dysfunction drugs. For example, chlorthalidone, propranolol, diazepam, cimetidine, and naproxen are some of the drugs that could cause erectile dysfunction. These drugs might help treat a particular disease; however, these can also cause hormonal imbalance, affect nerves and blood circulation, increasing the risk of erectile dysfunction in men.

According to the United Nations Economic and Social Commission for Asia and the Pacific, approximately 60% of the world’s geriatric population lives in Asia-Pacific. It is estimated that the number of elderly people will double from 547 million in 2016 to 1.3 billion by 2050. Therefore, the increase in the use of these drugs to treat the diseases mentioned above will continue to grow. encouraging the use of erectile dysfunction drugs, thereby driving the market. .

Additionally, obesity has been associated with an increased risk of erectile dysfunction. Sedentary lifestyle and rising incidence of obesity are expected to drive the emergency services market in the long term. Both smoking and alcoholism have been shown to increase the risk of erectile dysfunction.

Get a sample copy of the report @
https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1550

Development of new formulations to stimulate the global market

Localized drug delivery techniques for the treatment of erectile dysfunction, such as the use of creams and lozenges that exhibit better efficacy and performance, will be frequently sought after by healthcare professionals and institutions that have faced with the serious shortcomings of current drugs. The successful observations of combination therapy have been encouraging and market leaders are expected to focus on combination molecules such as PDE 5 inhibitors to gain significant advantage due to several benefits such as lower drug doses and reduced incidence of adverse effects.

Segment to dominate the market

In terms of drugs, the global erectile dysfunction drugs market has been categorized into Staxyn/Levitra, Stendra/Spedra and others. The Others segment includes Zydena, Mvix, Helleva, Vitaros, Caverject Impulse, generics and pipeline products. Tadalafil sales have exceeded Sildenafil Citrate sales due to Sildenafil Citrate patent expiration in major European countries. The entry of generic competition into these markets following the loss of exclusivity will lead to a rapid and severe decline in product revenues. tadalafil and Adcirca (tadalafil) filed for patent in major European and US markets in November 2020.

Survey before buying @
https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=1550

The retail pharmacy segment will dominate the market

Based on the distribution channel, the global market has been divided into hospital pharmacies, retail pharmacies and online pharmacies. The retail pharmacy segment accounted for a major market share in 2020. The easy availability of pharmaceutical drugs such as retail pharmacies and the use of these drugs in the first line of treatment can be attributed to the large market share of the segment retail pharmacies.

North America will dominate the global market

In terms of region, the global erectile dysfunction (ED) drugs market has been segmented into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America led the global erectile dysfunction (ED) drugs market in 2020, followed by Asia-Pacific. The high prevalence and rising incidence of erectile dysfunction in the United States and Canada and the high adoption of brand name treatments for erectile dysfunction can be attributed to the dominance of the US market. However, decreasing healthcare costs and decreasing hospitalization rates are expected to limit the market in North America during the forecast period.

Competition Landscape

The global erectile dysfunction (ED) drugs market is fragmented in terms of number of players. The major players in the global market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, Vivus, Inc., and Teva Pharmaceutical Industries Ltd. Manufacturers launch new products on the international market. to tap into the unmet needs of erectile dysfunction. Other prominent players operating in the global market include SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Futura Medical plc.

Contact

Rohit Bhisey
Transparency Market Research Inc.
HEADQUARTERS IN THE CITY CENTER,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
United States – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Blog: https://tmrblog.com
Email: [email protected]

About Us

Transparency Market Research, a global market research firm registered in Wilmington, Delaware, USA, provides personalized research and advisory services. The company examines the factors that shape demand dynamics in various markets. Market insights and insights assess opportunities in various segments. Opportunities in segments based on source, application, demographics, sales channel, and end-use are analyzed which will determine the growth of the markets over the next decade.

Our proprietary blend of quantitative forecasting and trend analysis delivers forward-looking insights to thousands of decision makers, made possible by experienced teams of analysts, researchers and consultants. Proprietary data sources and the various tools and techniques we use always reflect the latest trends and information. With a broad research and analytical capability, Transparency Market Research uses rigorous primary and secondary research techniques in all of its trade reports.

For more information on research on leading industries, visit our YouTube channel and click subscribe for future update – https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

This press release was published on openPR.

Share.

Comments are closed.